Neil John Mchugh

Neil John Mchugh's AcademicInfluence.com Rankings

Neil John Mchugh

Philosophy

#9400

World Rank

#12954

Historical Rank

Logic

#6380

World Rank

#7892

Historical Rank

philosophy Degrees

Neil John Mchugh

Biology

#12927

World Rank

#16435

Historical Rank

Immunology

#874

World Rank

#897

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Neil John Mchugh's Degrees

Doctorate Medicine Harvard University
PhD Immunology Stanford University

Why Is Neil John Mchugh Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Neil John Mchugh's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Treatment recommendations for psoriatic arthritis (2008) (796)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis (2016) (764)
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. (2006) (663)
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies (2011) (477)
BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. (2005) (473)
Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis (2010) (367)
Corrigendum: Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis (2015) (365)
Development and initial validation of an updated version of the British Isles Lupus Assessment Group ’ s disease activity index for patients with systemic lupus erythematosus (2005) (352)
European multicentre study to define disease activity criteria for systemic sclerosis.* II. Identification of disease activity variables and development of preliminary activity indexes (2001) (320)
Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. (1994) (316)
Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. (2003) (315)
A randomized placebo-controlled trial of methotrexate in psoriatic arthritis (2012) (313)
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005 (2005) (288)
Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. (2009) (274)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus‐Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis (2018) (255)
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project) (2012) (246)
Development and Assessment of a Computerized Index of Clinical Disease Activity in Systemic Lupus Erythematosus (1988) (217)
Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. (2007) (203)
International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials (2016) (175)
Quantitative nailfold capillaroscopy findings in a population with connective tissue disease and in normal healthy controls. (1996) (167)
Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis (2015) (162)
A polymorphism in the CTGF promoter region associated with systemic sclerosis. (2007) (159)
The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients (2010) (159)
Autoantibodies in myositis (2018) (147)
The EuroMyositis registry: an international collaborative tool to facilitate myositis research (2017) (146)
Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study (2014) (141)
Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study) (2013) (139)
Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis (2016) (135)
Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. (2007) (134)
Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis (2013) (132)
Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset (2014) (128)
The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. (2005) (126)
The ClASsification for Psoriatic ARthritis (CASPAR) Criteria – A Retrospective Feasibility, Sensitivity, and Specificity Study (2012) (126)
Numerical scoring for the BILAG-2004 index (2010) (124)
A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren’s Syndrome (2015) (122)
Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study (2016) (119)
Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis (2011) (117)
Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. (2007) (116)
European multicentre study to define disease activity criteria for systemic sclerosis.* I. Clinical and epidemiological features of 290 patients from 19 centres (2001) (114)
Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). (1988) (113)
HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. (2007) (113)
Guideline for anti-TNF-α therapy in psoriatic arthritis (2005) (112)
Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. (2006) (112)
Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study (2011) (107)
Percutaneous screw fixation of acetabular fractures with CT guidance: preliminary results of a new technique. (1992) (107)
Novel autoantibodies and clinical phenotypes in adult and juvenile myositis (2011) (106)
The BILAG-2004 index is sensitive to change for assessment of SLE disease activity (2009) (104)
Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions (2009) (103)
Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease (2000) (102)
International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. (2009) (102)
Work disability in psoriatic arthritis: a systematic review. (2012) (97)
British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus (2007) (97)
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS) (2017) (97)
Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort (2017) (96)
Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. (2007) (96)
Clinical Utility of Random Anti–Tumor Necrosis Factor Drug–Level Testing and Measurement of Antidrug Antibodies on the Long‐Term Treatment Response in Rheumatoid Arthritis (2015) (95)
Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study (2010) (94)
Infusion of iloprost, a prostacyclin analogue, for treatment of Raynaud's phenomenon in systemic sclerosis. (1988) (94)
Health-related utility values of patients with primary Sjögren's syndrome and its predictors (2013) (92)
Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. (2006) (90)
Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016 (2017) (86)
The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. (2013) (85)
Arthropathy of hands and feet in systemic lupus erythematosus. (1990) (83)
Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum". (2013) (82)
Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris (2011) (80)
Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review (2014) (77)
Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanisms? (2013) (77)
Muscle Biopsy Findings in Combination With Myositis‐Specific Autoantibodies Aid Prediction of Outcomes in Juvenile Dermatomyositis (2016) (77)
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). (2014) (75)
Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. (2008) (72)
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus (2015) (72)
Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. (2013) (71)
Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. (2015) (70)
Evidence for unique association signals in SLE at the CD28-CTLA4-ICOS locus in a family-based study. (2006) (69)
Tumour necrosis factor‐α polymorphism and the HLA‐Cw*0602 allele in psoriatic arthritis (2002) (69)
Mortality in Psoriatic Arthritis – A Single-center Study from the UK (2010) (69)
Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines (2016) (68)
The Influence of the HLA-DRB1 rheumatoid arthritis shared epitope on the clinical characteristics and radiological outcome of psoriatic arthritis. (2003) (68)
Guideline for anti-TNF-alpha therapy in psoriatic arthritis. (2005) (65)
Psoriatic arthritis: clinical subgroups and histocompatibility antigens. (1987) (65)
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register (2017) (63)
Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. (2013) (63)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015 (2015) (61)
Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups (2019) (61)
The diagnostic utility of autoantibodies in adult and juvenile myositis (2013) (60)
BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000 (2007) (60)
Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. (2015) (59)
Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort (2017) (58)
Pregnancy outcome and autoantibodies in connective tissue disease. (1989) (57)
Anticardiolipin and antineutrophil antibodies in giant cell arteritis. (1990) (57)
The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis (2018) (57)
Observational Study of Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis (2010) (57)
Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. (2015) (56)
Comparison of infrared thermography and laser speckle contrast imaging for the dynamic assessment of digital microvascular function. (2012) (56)
A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography (2018) (55)
The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity (2020) (54)
Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis (2018) (54)
HLA-DR antigens and anticardiolipin antibodies in patients with systemic lupus erythematosus. (1989) (54)
Lack of agreement between rheumatologists in defining digital ulceration in systemic sclerosis. (2009) (54)
Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis (2017) (52)
Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis (2008) (52)
Mortality in systemic sclerosis—a single centre study from the UK (2013) (50)
Serum Soluble Bone Turnover Biomarkers in Psoriatic Arthritis and Psoriatic Spondyloarthropathy (2015) (50)
Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis. (2012) (49)
Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis (2010) (49)
Connective Tissue Disease and Autoantibodies in the Kindreds of 63 Patients with Systemic Sclerosis (1993) (48)
Use of Laser Speckle Contrast Imaging to Assess Digital Microvascular Function in Primary Raynaud Phenomenon and Systemic Sclerosis: A Comparison Using the Raynaud Condition Score Diary (2015) (48)
Endothelin axis polymorphisms in patients with scleroderma. (2006) (47)
Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. (2002) (47)
Interleukin 1α, interleukin 1β and interleukin 1 receptor gene polymorphisms in psoriatic arthritis (2004) (47)
Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study (2017) (47)
Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis (2018) (46)
Non organ based laboratory markers in systemic sclerosis. (2003) (45)
Exploring ankylosing spondylitis-associated ERAP1, IL23R and IL12B gene polymorphisms in subphenotypes of psoriatic arthritis. (2013) (44)
Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study (2018) (44)
The effect of pregnancy on the onset of psoriatic arthritis. (1989) (44)
Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity. (1994) (44)
MHC class II, tumour necrosis factor α, and lymphotoxin α gene haplotype associations with serological subsets of systemic lupus erythematosus (2005) (43)
Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies (2019) (43)
HLA-DPB1 associations differ between DRB1*03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy. (2009) (43)
Influence of the cold challenge on the discriminatory capacity of the digital distal-dorsal difference in the thermographic assessment of Raynaud's phenomenon. (2011) (41)
Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (2017) (41)
Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort (2012) (41)
Drug use and toxicity in psoriatic disease: focus on methotrexate. (2008) (41)
Expression of the cutaneous lymphocyte antigen and its counter-receptor E-selectin in the skin and joints of patients with psoriatic arthritis. (1997) (41)
Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study (2017) (40)
Serologic abnormalities in systemic sclerosis. (1999) (40)
PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials (2018) (38)
A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies (2021) (38)
Numerical scoring for the Classic BILAG index (2009) (38)
Enhanced Patient Involvement and the Need to Revise the Core Set — Report from the Psoriatic Arthritis Working Group at OMERACT 2014 (2015) (36)
Predictors of health-related quality of life and fatigue in systemic sclerosis: evaluation of the EuroQol-5D and FACIT-F assessment tools (2012) (36)
Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) — Report of the OMERACT 10 PsA Special Interest Group (2011) (36)
Presence of anti-eukaryotic initiation factor-2B, anti-RuvBL1/2 and anti-synthetase antibodies in patients with anti-nuclear antibody negative systemic sclerosis (2018) (36)
Characterization of antinucleolar antibody reactivity in patients with systemic sclerosis and their relatives. (1997) (36)
Human leukocyte antigen class II associations with systemic sclerosis in South Africans. (2004) (36)
Development of a Disease Activity and Responder Index for Psoriatic Arthritis — Report of the Psoriatic Arthritis Module at OMERACT 11 (2014) (36)
Association of markers for TGFβ3, TGFβ2 and TIMP1 with systemic sclerosis (2000) (35)
'It's more scary not to know': a qualitative study exploring the information needs of patients with systemic lupus erythematosus at the time of diagnosis. (2011) (35)
Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti–Tumor Necrosis Factor (2017) (35)
Patient Involvement in Outcome Measures for Psoriatic Arthritis (2014) (35)
Presentation of SLE in UK primary care using the Clinical Practice Research Datalink (2017) (35)
Joint and soft tissue injections: a survey of general practitioners. (2005) (35)
Mortality and Causes of Death in Psoriatic Arthritis (2012) (34)
Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice (2017) (33)
Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients (2017) (33)
Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials (2016) (33)
Maximum blood flow and microvascular regulatory responses in systemic sclerosis. (2007) (33)
Psoriatic arthritis--emerging concepts. (2001) (33)
Composite Measures in Psoriatic Arthritis: GRAPPA 2008 (2010) (31)
Patient-reported outcome instruments for assessing Raynaud’s phenomenon in systemic sclerosis: A SCTC vascular working group report (2018) (31)
Myositis Specific and Associated Autoantibodies in the Diagnosis and Management of Juvenile and Adult Idiopathic Inflammatory Myopathies (2014) (30)
Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study (2017) (30)
Microparticle subpopulations are potential markers of disease progression and vascular dysfunction across a spectrum of connective tissue disease (2016) (30)
Genetic association study of NF-κB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy (2011) (30)
Apoptosis-new clues to the pathogenesis of Sjögren's syndrome? (2000) (30)
The cervical spine in psoriatic arthritis: a clinical and radiological study. (1994) (29)
Tumor necrosis factor promoter polymorphism TNF*-857 is a risk allele for psoriatic arthritis independent of the PSORS1 locus. (2011) (29)
Histological heterogeneity in a large clinical cohort of juvenile idiopathic inflammatory myopathy: analysis by myositis autoantibody and pathological features (2019) (29)
Autoantibodies to mitochondrial and centromere antigens in primary biliary cirrhosis and systemic sclerosis (1990) (29)
Expression of myxovirus‐resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis (2018) (29)
Characterisation of anticytoplasmic antibodies and their clinical associations. (1995) (29)
Polymorphisms in IL-1B distinguish between psoriasis of early and late onset. (2014) (29)
Pathogenic mechanisms of disease in myositis: autoantigens as clues (2009) (28)
Anticardiolipin and antinuclear antibodies in cancer patients--a case control study. (2000) (28)
Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. (2015) (28)
Effect of anti‐TNF and conventional synthetic disease‐modifying anti‐rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis (2016) (27)
Atypical Behçet's disease with peripheral erosive arthropathy and pyoderma gangrenosum. (1992) (27)
The contribution of platelets to the pathogenesis of Raynaud's phenomenon and systemic sclerosis (2013) (26)
Anti-HMGCR Autoantibodies in Juvenile Idiopathic Inflammatory Myopathies Identify a Rare but Clinically Important Subset of Patients (2017) (26)
Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting (2016) (26)
Arthritis in Idiopathic Inflammatory Myopathy: Clinical Features and Autoantibody Associations (2014) (25)
Lupus-like syndrome associated with the use of minocycline. (1994) (25)
Developing classification criteria for peripheral joint psoriatic arthritis. Step I. Establishing whether the rheumatologist's opinion on the diagnosis can be used as the "gold standard". (2006) (25)
Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome? (2015) (25)
Feasibility, Reliability, and Sensitivity to Change of Four Radiographic Scoring Methods in Patients With Psoriatic Arthritis (2014) (25)
Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History (2015) (25)
Fatigue in primary Sjögren’s syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study (2019) (24)
Familial scleroderma--evidence for environmental versus genetic trigger. (1994) (24)
Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor–treated rheumatoid arthritis patients (2019) (24)
The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review (2015) (23)
Interleukin 1alpha, interleukin 1beta and interleukin 1 receptor gene polymorphisms in psoriatic arthritis. (2004) (23)
Systemic lupus erythematosus and dysregulated apoptosis-what is the evidence? (2002) (23)
Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study (2018) (23)
Brief Report: Anti–Eukaryotic Initiation Factor 2B Autoantibodies Are Associated With Interstitial Lung Disease in Patients With Systemic Sclerosis (2016) (22)
Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools (2014) (21)
Implications of the diversity of class I HLA associations in psoriatic arthritis. (2016) (20)
The impact of group education on participants' management of their disease in lupus and scleroderma. (2004) (20)
The association of primary biliary cirrhosis and systemic sclerosis is not accounted for by cross reactivity between mitochondrial and centromere antigens. (1994) (20)
The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort (2018) (19)
A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis (2017) (18)
Symptoms of Raynaud’s phenomenon (RP) in fibromyalgia syndrome are similar to those reported in primary RP despite differences in objective assessment of digital microvascular function and morphology (2016) (18)
The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis (2020) (18)
A rare coding allele in IFIH1 is protective for psoriatic arthritis (2017) (18)
HLA-DQB1 associations with anti-topoisomerase-1 antibodies in patients with systemic sclerosis and their first degree relatives. United Kingdom Systemic Sclerosis Study Group. (1994) (17)
A polymorphism in the promoter region of the CD86 (B7.2) gene is associated with systemic sclerosis (2006) (17)
Pulmonary artery hypertension as the presenting feature of systemic sclerosis sine scleroderma. (2008) (17)
Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. (2020) (17)
Papular lesions and cutaneous lupus erythematosus: a comparative clinical and histological study using monoclonal antibodies. (1988) (16)
Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility (2011) (16)
A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus (2013) (16)
Evaluation of the Economic Burden of Psoriatic Arthritis and the Relationship Between Functional Status and Healthcare Costs (2019) (16)
Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis (2019) (16)
Frequency of autoantibodies to a major epitope on the carboxyl terminal fragment of CENP-B in patients with autoimmune disease. (1995) (15)
Segregation of autoantibodies with disease in monozygotic twin pairs discordant for systemic sclerosis. Three further cases. (1995) (15)
Early Psoriatic Arthritis. (2015) (15)
Antinuclear Antibodies and Clinical Associations in a British Cohort with Limited Cutaneous Systemic Sclerosis (2011) (15)
Psoriatic Nail Dystrophy Is Associated with Erosive Disease in the Distal Interphalangeal Joints in Psoriatic Arthritis: A Retrospective Cohort Study (2018) (14)
MHC class II associations with autoantibody and T cell immune responses to the scleroderma autoantigen topoisomerase I. (2000) (14)
A prospective study of pregnancy outcome in women screened at a routine antenatal clinic for anticardiolipin antibodies (1993) (14)
Other seronegative spondyloarthropathies (2002) (13)
Patient Participation in Psoriasis and Psoriatic Arthritis Outcome Research: A Report from the GRAPPA 2013 Annual Meeting (2014) (13)
HLA – DPB 1 associations differ between DRB 1 * 03 positive anti-Jo-1 and anti-PM-Scl antibody positive idiopathic inflammatory myopathy (2009) (12)
The BILAG-2004 systems tally—a novel way of representing the BILAG-2004 index scores longitudinally (2012) (12)
Autoantibodies to the p140 Autoantigen NXP-2 in Adult Dermatomyositis (2009) (12)
Abnormal cardiac enzymes in systemic sclerosis: a report of four patients and review of the literature (2014) (12)
Trajectory of radiographic change over a decade: the effect of transition from conventional synthetic disease-modifying antirheumatic drugs to anti-tumour necrosis factor in patients with psoriatic arthritis (2018) (11)
Polyarthritis and angioimmunoblastic lymphadenopathy. (1987) (11)
Antiphospholipid syndrome with proliferative vasculopathy and bowel infarction. (2000) (11)
Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-recommended Next Steps (2020) (11)
Replication of a distinct psoriatic arthritis risk variant at the IL23R locus (2016) (11)
Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren’s syndrome (2019) (11)
Defining anti-synthetase syndrome: a systematic literature review. (2022) (11)
Connective tissue disease and autoantibodies in the kindreds of 63 patients with systemic sclerosis. The United Kingdom Systemic Sclerosis Study Group. (1993) (10)
HLA class II restriction of autoantibody production in patients with systemic lupus erythematosus. (1991) (10)
Microvascular responses following digital thermal hyperaemia and iontophoresis measured by laser Doppler imaging in idiopathic inflammatory myopathy. (2007) (10)
Treatment Algorithms for Early Psoriatic Arthritis: Do They Depend on Disease Phenotype? (2012) (10)
Building Bridges between Researchers and Patient Research Partners: A Report from the GRAPPA 2014 Annual Meeting (2015) (10)
Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry. (2018) (10)
'To suddenly have a name for this thing… was wonderful': the patient's experience of receiving a diagnosis of systemic lupus erythematosus. (2012) (10)
Association of markers for TGFbeta3, TGFbeta2 and TIMP1 with systemic sclerosis. (2000) (9)
Clinical Associations Of Anti-p140 Autoantibodies In Adult Myositis (2010) (9)
Joint count reliability in psoriatic arthritis observational trials--an unreported problem. (2012) (9)
Spontaneous neutrophil activation in patients with primary Raynaud's phenomenon and systemic sclerosis. (1992) (9)
Verna Wright Lecture: Psoriatic Arthritis: The Need for Early Intervention (2015) (9)
Genetic factors in psoriatic arthritis (2005) (8)
Developing standardised treatment for adults with myositis and different phenotypes: an international survey of current prescribing preferences. (2016) (8)
Vacuum-assisted closure therapy: a novel treatment for wound healing in systemic sclerosis. (2011) (8)
Gender stratified adjustment of the DAS28-CRP improves inter-score agreement with the DAS28-ESR in rheumatoid arthritis (2018) (7)
Frequency and clinical associations of anti-chromo antibodies in connective tissue disease. (1994) (7)
Diagnosis and initial management in psoriatic arthritis: a qualitative study with patients (2019) (7)
The myositis clinical phenotype associated with anti-Zo autoantibodies: a case series of nine UK patients (2019) (7)
Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. (2017) (7)
Estimating the diagnostic accuracy of rheumatoid factor in UK primary care: a study using the Clinical Practice Research Datalink. (2015) (7)
Novel Composite Radiographic Score for Longitudinal Observational Studies of Psoriatic Arthritis: A Proof-of-concept Study (2016) (7)
Clinical Phenotypes of Caucasian Adult and Juvenile Dermatomyositis Patients with Anti-MDA5 Autoantibodies. (2012) (7)
Minocycline-induced lupus and autoimmune phenomena (1999) (7)
Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer (2018) (6)
Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases (2020) (6)
NEGATIVE RHEUMATOID FACTOR IN PRIMARY CARE DELAYS REFERRAL OF PATIENTS WITH RHEUMATOID ARTHRITIS (2014) (6)
Combined corticosteroid and aspirin treatment for the high risk lupus pregnancy (1993) (6)
Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting (2015) (6)
Myositis autoantibodies: recent perspectives (2020) (6)
A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing (2022) (6)
Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study (2021) (6)
Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties (2019) (6)
Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort (2013) (6)
MUSCLE BIOPSY IN COMBINATION WITH MYOSITIS-SPECIFIC AUTOANTIBODIES AIDS PREDICTION OF OUTCOMES IN JUVENILE DERMATOMYOSITIS (2016) (6)
HLA class II restriction of autoantibody production in patients with systematic lupus erythematosus (2004) (6)
Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling (2022) (6)
The Clinical Aspects of Autoantibodies (2012) (6)
Reactivity in ELISA with DNA-loaded nucleosomes in patients with proliferative lupus nephritis. (2015) (6)
Elevated anticardiolipin antibodies in a patient with vibration-white-finger, valvular heart disease and psoriatic arthritis (1993) (6)
Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models (2021) (6)
Autoantibodies in connective tissuedisease. (2019) (5)
British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy (2022) (5)
Impact of anti-centromere antibodies on pulmonary function test results in patients with systemic sclerosis without established or suspected pulmonary disease (2014) (5)
Epidemiology of systemic sclerosis in the UK: an analysis of the Clinical Practice Research Datalink. (2020) (5)
Evaluating factors influencing screening for pulmonary hypertension in systemic sclerosis: does disparity between available guidelines influence clinical practice? (2012) (5)
Bilateral hip replacements in a man with cystic fibrosis and episodic arthritis. (1997) (5)
Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA (2019) (5)
Guidelines for the Treatment of Psoriatic Arthritis with Biologics the British Society for Rheumatology 2012 Guidelines for the Treatment of Psoriatic Arthritis with Biologics (5)
Systematic protein-protein interaction and pathway analyses in the idiopathic inflammatory myopathies (2016) (4)
Attitudes Toward Patient-Reported Outcome Instruments for the Assessment of Raynaud’s Phenomenon in Systemic Sclerosis (2016) (4)
Anti-EIF2B: A Novel Interstitial Lung Disease Associated Autoantibody in Patients with Systemic Sclerosis (2012) (4)
The Relationship Between the Vitamin D Receptor Gene and Anti-155/140 Antibodies in UK Caucasians with Idiopathic Inflammatory Myositis (2009) (4)
Morphoea profunda and its relationship to eosinophilic fasciitis (2018) (4)
Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models (2020) (4)
Exploring the illness representations of people with psoriatic arthritis: a secondary analysis of focus group data (2018) (4)
Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study (2018) (4)
Serological subsets of juvenile idiopathic inflammatory myopathies - an update (2016) (4)
Subgroups in psoriatic arthritis. (1994) (4)
BSRBR-RA Contributors Group (2019). Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology (2019) (4)
Using Bayesian networks to identify musculoskeletal symptoms influencing the risk of developing psoriatic arthritis in people with psoriasis (2021) (3)
A surprise behind a case of winter vomiting virus (2013) (3)
Clinical Differences Between Adult and Juvenile Dermatomyositis Associated with Anti-NXP2 Autoantibodies. (2012) (3)
Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part two (2017) (3)
Features and recommended treatment of systemic sclerosis (2008) (3)
Oral Abstracts 1: Connective Tissue DiseaseO1. Long-Term Outcomes of Children Born to Mothers with SLE (2013) (3)
Pregnancy loss, menopause, and the onset of rheumatoid arthritis. (1990) (3)
049. INTERVAL BETWEEN ONSET OF PSORIASIS AND PSORIATIC ARTHRITIS: COMPARING THE UNITED KINGDOM CLINICAL PRACTICE RESEARCH DATALINK WITH A HOSPITAL-BASED COHORT (2017) (3)
Biologic Agents in Psoriasis: British Association of Dermatologists' Guidelines for Biologic Intervention for Psoriasis 2009 (2011) (3)
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. (2017) (3)
Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach (2013) (3)
Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire (2021) (3)
Traditional Schemes for Treatment of Psoriatic Arthritis (2009) (3)
METHOTREXATE IS NOT DISEASE MODIFYING IN PSORIATIC ARTHRITIS: A NEW TREATMENT PARADIGM IS REQUIRED (2010) (3)
Current management of dermatomyositis (2012) (3)
Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. (2020) (2)
The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative (2018) (2)
Clinical associations of autoantibodies to a p155/140 KDA doublet in adult and juvenile dermatomyositis (2007) (2)
181. Developing Standardized Treatment for Adults with Myositis and Different Phenotypes (2014) (2)
PC23 MAXIMUM HYPERAEMIC RESPONSE AS A BIOLOGICAL REFERENCE FOR LASER DOPPLER BLOOD FLOW MEASUREMENTS (2004) (2)
Sub-phenotyping of juvenile dermatomyositis: can it assist clinical decisions? (2014) (2)
How good are the eular sjögren’s syndrome disease activity index, and eular sjögren’s syndrome patients reported index in predicting health status in primary sjögren’s syndrome? (2012) (2)
262 Longitudinal Assessment of Systemic Lupus Erythematosus Disease Activity: British Isles Lupus Assessment Group 2004, Systemic Lupus Erythematosus Disease Activity Index 2000 or Both? (2016) (2)
Role of ANA and Myositis Autoantibodies in Diagnosis (2019) (2)
Test Data in General Practice Are Not Missing at Random - Can We Identify When They Are? (2013) (2)
Lessons for clinical practice from biologics registers IP10. Establishing and Running a Biologics Register: Manchester - United (2011) (2)
175 Myositis-Specific Autoantibodies Rarely Coexist with Each Other: An Analysis of the Ukmyonet and Eumyonet Cohorts (2016) (2)
17. Anti-synthetase autoantibody is seen in patients with overlap myositis in the UK cohort of patients with Jveunile Dermatomyositis (2017) (2)
174 A diagnostic and treatment challenge: the prevalence and clinical associations of anti-HMG-CoA reductase autoantibodies in a large UK juvenile-onset myositis cohort (2016) (2)
Comparison of Three Screening Tools in Psoriatic Arthritis: The Contest Study (2012) (2)
The Diagnostic Accuracy Of Rheumatoid Factor Testing In Primary Care (2013) (2)
Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine (2022) (2)
Atypical antineutrophil cytoplasmic antibodies in patients with ankylosing spondylitis. (1995) (2)
Anti‐Golgi autoantibodies: prevalence and disease associations in a rheumatic disease population (2012) (2)
O44. An Integrative Analytical Approach to Subphenotyping of Juvenile Dermatomyositis (2015) (2)
Identification of autoantibodies to a novel autoantigen protein complex (EIF3) in polymyositis patients (2011) (2)
Corrigendum to: A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies (2021) (2)
Longitudinal profiling of the gut microbiome in patients with psoriatic arthritis and ankylosing spondylitis: a multicentre, prospective, observational study (2020) (1)
053. ANTI-SYNTHETASE AUTOANTIBODY IS SEEN IN PATIENTS WITH OVERLAP MYOSITIS IN THE UK COHORT OF PATIENTS WITH JUVENILE DERMATOMYOSITIS (2017) (1)
Conventional therapy of psoriatic arthritis: evidence-based review. (2011) (1)
Comment on: The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody–positive dermatomyositis: Reply (2019) (1)
Gene-Environmental Interaction of HLA-DRB1*03:01 and Smoking for the Development of Anti-Jo-1 Autoantibodies in Idiopathic Inflammatory Myopathies: A UK Study (2016) (1)
Chapter 11 – Clinical Outcome Measures in Psoriatic Arthritis (2007) (1)
ANTI-NXP2 AUTOANTIBODY STATUS IS A PREDICTOR OF CALCINOSIS IN OLDER BUT NOT YOUNGER CHILDREN WHO DEVELOP JUVENILE DERMATOMYOSITIS (2013) (1)
Impaired digital vascular function mimicking Raynaud's phenomenon as a complication of argon laser therapy in tuberous sclerosis. (2010) (1)
Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study. (2021) (1)
Raynaud’s phenomenon and macrocytic anaemia (2010) (1)
FRI0674 Applicability of the psaid12 questionnaire as a core outcome measurement in psa clinical trials: an evaluation using omeract filter 2.1 instrument selection criteria (2018) (1)
Basic (PS01–PS58) (2012) (1)
BHPR research: qualitative1. Complex reasoning determines patients’ perception of outcome following foot surgery in rheumatoid arhtritis (2012) (1)
Clinical and immunogenetic characteristics of patients with Autoantibodies to small ubiquitin-like modifier activating enzyme in dermatomyositis (2008) (1)
Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study (2021) (1)
The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. (2022) (1)
AB0735 SEVERITY OF NAIL PSORIASIS SCORE (SNAPS) DEMONSTRATES LONGITUDINAL CONSTRUCT VALIDITY AGAINST THE MODIFIED NAIL PSORIASIS SEVERITY INDEX (mNAPSI) IN AN OBSERVATIONAL COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS (2020) (1)
Corrigendum: Eligibility for clinical trials in primary Sjögren's syndrome: Lessons from the UK Primary Sjögren's Syndrome Registry [Rheumatology, 55, (2016) (544-552)] doi:10.1093/rheumatology/kev373 (2017) (1)
Connective Tissue Diseases. (1997) (1)
AB0839 RELIABILITY OF COMPOSITE MEASURES FOR THE ASSESSMENT OF PSORIATIC ARTHRITIS (2020) (1)
Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. (2021) (1)
O24 Low level detection of CTD-associated autoantibodies in patients with idiopathic pulmonary fibrosis confirms this as a robust phenotype when diagnosed on clinical grounds alone (2018) (1)
Comparison of responsiveness of BILAG-2004, SLEDAI-2000 and BILAG Systems Tally (BST). (2021) (1)
A MULTICENTRE RELIABILITY AND VALIDITY STUDY OF LASER SPECKLE CONTRAST IMAGING AND THERMOGRAPHY IN PATIENTS WITH RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS (2017) (1)
20 – CENTROMERE AUTOANTIBODIES (2007) (1)
THU0391 Axial Disease in Psoriatic Arthritis () Study: Serum-Soluble Bone-Turnover Biomarkers of Psoriatic Arthritis Phenotypes (2016) (1)
Response to: ‘Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria’ by Cavagna et al (2017) (1)
Use of ENCODE and eQTL data to identify potential functional genetic variants at the 5q31 psoriatic arthritis susceptibility locus (2013) (1)
048. RISK OF UVEITIS AND INFLAMMATORY BOWEL DISEASE IN PEOPLE WITH PSORIATIC ARTHRITIS: A POPULATION-BASED COHORT STUDY (2017) (1)
Oral abstracts 3: RA Treatment and outcomesO13. Validation of jadas in all subtypes of juvenile idiopathic arthritis in a clinical setting (2012) (1)
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. (2017) (1)
Muscle disorders111. The impact of fatigue in patients with idiopathic inflammatory myopathy: a mixed method study (2012) (1)
Autoantibodies in Raynaud’s Phenomenon (2015) (1)
O15. Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multi-Centre Register (2015) (1)
Exercise and rheumatoid arthritis: what's in it for us? (2010) (1)
O57. Autoantibody in Juvenile Dermatomyositis Reflects Disease Activity: Results of a Pilot Study (2014) (1)
Comment on: The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity: reply. (2020) (1)
THU0006 Application of machine learning methods for prediction modelling of psoriatic arthritis in patients with psoriasis (2018) (1)
Genome-wide imputation identifies novel associations and localises signals in idiopathic inflammatory myopathies. (2022) (1)
Prediction of outcomes in juvenile myositis (2016) (1)
Spondylarthropathies (including psoriatic arthritis) 244. Validity of Colour Doppler and Spectral Doppler Ultrasound of Sacroilicac Joints Againts Physical Examination as Gold Standard (2011) (1)
Infusion ofIloprost, a prostacyclin analogue, for treatmentofRaynaud's phenomenon insystemic sclerosis (2013) (0)
EUROQOL-reported health disability demonstrates reduced quality of life remaining constant over time in established psoriatic arthritis (2011) (0)
The BILAG-2004 Systems Tally-a Novel Way of Analysing the BILAG-2004 Scores (2011) (0)
Laboratory features—enzymes and biomarkers (2018) (0)
Diaschisis lesions following traumatic brain injury (2017) (0)
036. THE ILLNESS PERCEPTIONS OF PEOPLE WITH PSORIATIC ARTHRITIS: A SECONDARY ANALYSIS OF FOCUS GROUP DATA (2017) (0)
A study of obesity, BMI, smoking and alcohol as risk factors for psoriatic arthritis (2020) (0)
OP0224 CONTINUOUS COMPOSITE MEASURES FOR ROUTINE CARE IN PSORIATIC ARTHRITIS: THRESHOLDS OF MEANING AND CLINICALLY IMPORTANT DIFFERENCE ESTIMATES FOR THE 3 AND 4 VAS SCALES FROM A UK MULTICENTRE STUDY (2021) (0)
086 A longitudinal analysis of prevalence of sustained remission and low disease activity in rheumatoid arthritis patients treated with anti-tumour necrosis factor: an analysis of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (2018) (0)
Gene networks describe symptom based phenotypes in primary Sjogren's syndrome (2018) (0)
189 Are we Optimising Therapies in Psoriatic Arthritis? A Survey of UK Practice (2016) (0)
220 Discrepancy between solid-phase immunoassays and immunoprecipitation in detecting anti-TIF1 gamma in patients with myositis (2019) (0)
Sa1657: NEW LINKS BETWEEN PSORIATIC ARTHRITIS AND THE GUT MICROBIOME SUGGEST A STRONGER ROLE OF THE GUT-JOINT AXIS (2022) (0)
IN UK CAUCASIAN ADULT AND JUVENILE-ONSET DERMATOMYOSITIS (DM), THE VITAMIN D RECEPTOR GENE (VDR) IS ASSOCIATED WITH POSSESSION OF ANTI-155/140 ANTIBODIES (2009) (0)
322. Patients with Refractory Systemic Lupus Erythematosus Requiring Biologic Therapy Have Significant Levels of Baseline Co-Morbidities: Results from a National Multi-Centre Register (2014) (0)
SAT0331 CHIPPING AWAY AT POLYMYOSITIS: A RETROSPECTIVE REVIEW AT A TERTIARY MYOSITIS CENTRE (2020) (0)
SAT0182 THE ASSOCIATION BETWEEN AUTOANTIBODIES AND RITUXIMAB RESPONSE IN SYSTEMIC LUPUS ERYTHEMATOSUS (2020) (0)
SAT0399 RISK OF OSTEOARTHRITIS IN AN INCIDENT COHORT OF PEOPLE WITH PSORIATIC ARTHRITIS: A POPULATION-BASED COHORT STUDY (2020) (0)
242 Baseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR) (2019) (0)
AB0803 EXPERIENCES OF SCREENING AND DIAGNOSIS FROM THE PERSPECTIVE OF PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS (PSA) (2021) (0)
InUK Caucasian adult and juvenile onset idiopathic inflammatory myopathy (IIM), the PTPN22 1858 -> T polymorphism confers disease susceptibility independent of HLA-DRB1*03 (2008) (0)
Frequency andclinical associations ofanti-chromo antibodies inconnective tissue disease (1994) (0)
Development and testing of new candidate psoriatic arthritis screening questionnaires combining optimal questions from existing tools Authors (2015) (0)
IX Eular Workshop for Rheumatology Research (1989) (0)
Comment on: The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity: reply. (2020) (0)
i065 The diagnostic utility of interstitial lung disease serology (2018) (0)
Influence of the cold challenge on the discriminatory capacity of the digital distal-dorsal thermal gradient in the thermographic assessment of Raynaud's phenomenon (2011) (0)
O55. Prevalence of Autoantibodies to Hmgcr in Myositis Patients (2014) (0)
Clinical associations of autoantibodies to a p155/140kDa doublet in adult dermatomyositis is a major autoantigen target in juvenile dermatomyositis (2007) (0)
MATTERS ARISING Effect of gold treatment on cytokine expression in synovium (0)
Psoriatic arthritis screening tools: study design and methodologic challenges – reply from authors (2014) (0)
POS0111 DEVELOPMENT OF DAMAGE AND MORTALITY IN AN INCEPTION COHORT OF SLE PATIENTS (2021) (0)
BSRBR-RA Contributors Group (2019). Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. Rheumatology , (2019) (0)
Ro52, Myositis, and Interstitial Lung Disease (2022) (0)
Plain radiography (2018) (0)
Symptoms and diagnosis of psoriatic arthritis (2013) (0)
Methotrexate in Psoriatic Arthritis : Results from 2 Clinical Trials Comparison of Etanercept Monotherapy and Combination Therapy with and Gaia (2016) (0)
The BILAG-2004 index is associated with development of new damage in SLE. (2022) (0)
Investigating a Novel Locus For Psoriatic Arthritis (2013) (0)
Adalimumab treatment is effective in patients with psoriatic arthritis (PSA) in day-to-day clinical practice - Results from the stereo trial (2008) (0)
A new era for collaboration? (2018) (0)
Concurrent Oral 6 – Spondylarthropathies [OP40–OP47] OP40. Association of IL23R and IL12B Polymorphisms with Psoriatic Arthritis (2010) (0)
Vacuum assisted closure therapy:A novel treatment for refractory digital ulceration in systemic sclerosis (2010) (0)
POS0288 A KEY TIF1γ EPITOPE MAY FACILITATE THE IDENTIFICATION OF PATIENTS AT HIGHEST RISK OF CANCER ASSOCIATED MYOSITIS (2021) (0)
OA30 Systemic sclerosis and cancer in the UK: an epidemiological analysis using the Clinical Practice Research Datalink (2023) (0)
Sub-phenotyping of juvenile dermatomyositis (2015) (0)
CHARACTERISATION OF UK ANTI-HMGCR+ ANTIBODY ASSOCIATED MYOSITIS (2016) (0)
Laboratory Tests for Psoriatic Arthritis (2016) (0)
Treatments for psoriatic arthritis (2006) (0)
Preliminary Rasch analysis of SLEDAI-2000 index: An ordinal scale index with internal construct validity (2006) (0)
Clinical and Autoantibody Associations in Myositis Patients with Anti p155/140kDa Autoantibodies - A Multicenter European Study (2011) (0)
SAT0011 Replication of A Distinct Psoriatic Arthritis Risk Variant at IL23R (2016) (0)
68. PROGRESSION OF FUNCTIONAL DISABILITY IN PSORIATIC ARTHRITIS: A COMPARISON OF CONVENTIONAL DMARDS AND ANTI-TNF THERAPY (2010) (0)
Advancing research paradigms and pathophysiological pathways in psoriatic arthritis and ankylosing spondylitis: Proceedings of the 2017 Platform for the Exchange of Expertise and Research (PEER) meeting. (2019) (0)
Risk of Osteoarthritis in an Incident Cohort of People With Psoriatic Arthritis: A Population-based Cohort Study (2020) (0)
Concurrent oral 4 – Connective tissue disease OP22. B Cell Numbers and Phenotype at Clinical Relapse Following Rituximab Therapy Differ in SLE Patients According to Anti-Dsdna Antibody Titres (2011) (0)
POS0106 BILAG-2004 LDA AND BST LDA ARE VALID TREAT TO TARGET IN SLE (2021) (0)
Authors' reply (1995) (0)
P163 Association between biomarkers and therapeutic pathway in patients with SLE (2021) (0)
Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register (2014) (0)
A NEGATIVE RHEUMATOID FACTOR RESULT IN PRIMARY CARE SIGNIFICANTLY DELAYS THE TIME TO DIAGNOSIS OF RHEUMATOID ARTHRITIS: A STUDY USING THE CLINICAL PRACTICE RESEARCH DATALINK (2015) (0)
069. CONSTRUCT VALIDITY, RESPONSIVENESS AND MINIMALLY IMPORTANT DIFFERENCE OF THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 IN PSORIATIC ARTHRITIS (2017) (0)
FRI0218 IMMUNOPHENOTYPIC SUBGROUPS OF SLE DEFINED BY AUTOANTIBODIES, GENE EXPRESSION AND FLOW CYTOMETRIC ANALYSIS (2019) (0)
Autoantibodies in juvenile dermatomyositis, scleroderma and overlap syndromes (2006) (0)
BHPR: Audit and Clinical Evaluation103. Dental Health in Children and Young Adults with Inflammatory Arthritis: Access to Dental Care (2013) (0)
A novel composite radiographic score for longitudinal observational studies of Psoriatic Arthritis: Reductive X-ray Score for Psoriatic Arthritis (ReXSPA)- a proof of concept study (2016) (0)
Autoantibody Associations Arthritis in Idiopathic Inflammatory Myopathy: Clinical Features and (2014) (0)
Systemic sclerosis: HLA antigens, autoantibodies and the brain. (1994) (0)
Preliminary Validation of the Severity of Nail Psoriasis Score (SNAPS) for the Assessment of Nail Psoriasis in Patients With Psoriatic Arthritis (2021) (0)
CONNECTIVE TISSUE DISORDERS AND VASCULITIS ORAL ABSTRACTSO13. AUTOANTIBODY SUBTYPE IN PATIENTS WITH JUVENILE-ONSET MYOSITIS INFLUENCES TREATMENT RECEIVED (2017) (0)
PReS-FINAL-2130: Antibodies to MDA5 correlate with a distinct phenotype in children with juvenile dermatomyositis, including higher risk of lung involvement and ulcerative skin disease (2013) (0)
O54 Differences in DAS28-CRP and DAS28-ESR Influence Disease Activity Stratification in Rheumatoid Arthritis and Could Influence the Use of Biologics, Treatment Efficacy Evaluations and Decisions Regarding Treat-To-Target: An Analysis Using the British Society for Rheumatology Rheumatoid Arthritis R (2016) (0)
Basic science232. Certolizumab pegol prevents pro-inflammatory alterations in endothelial cell function (2012) (0)
117 Anti-TIF-1 antibody positivity is associated with a five-fold increase in cancer risk in the idiopathic inflammatory myopathies (2018) (0)
Anti-TIF-1 Antibody Positivity Is Associated with a Five-Fold Increase in Cancer Risk in the Idiopathic Inflammatory Myopathies (2017) (0)
肥胖、BMI、吸烟和饮酒作为银屑病关节炎风险因素的研究 (2020) (0)
The Journal of Rheumatology Interphalangeal Joints in Psoriatic Arthritis: A Retrospective Cohort Study Psoriatic Nail Dystrophy Is Associated with Erosive Disease in the Distal (2019) (0)
201 Retrospective Study of the Management of Psoriatic Arthritis with Tumour Necrosis Factor Inhibitors in the UK: Capture Study Preliminary Analysis (2016) (0)
Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. (2022) (0)
The Journal of Rheumatology Interphalangeal Joints in Psoriatic Arthritis: A Retrospective Cohort Study Psoriatic Nail Dystrophy Is Associated with Erosive Disease in the Distal (2019) (0)
Genetic association study of NF-KB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopath (IIM) (2008) (0)
BILAG-2004 index: A reliable tool for assessment of SLE activity (2005) (0)
OP0128 PTPN22 is Associated with Susceptibility to Psoriatic Arthritis but not Psoriasis: Evidence for a Further PSA-Specific Risk Locus (2015) (0)
The 'Severity of Nail Psoriasis Score' (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis (2019) (0)
Systemic lupus erythematosus: a pragmatic guide to current management IP49. Diagnosing and Treating Systemic Lupus Erythematosus (2011) (0)
O47 A Dense Fine Speckle Pattern on Immunofluorescence is Strongly Associated with the Development of Uveitis in Children with Juvenile Idiopathic Arthritis (2016) (0)
AB0736 SEVERITY OF NAIL PSORIASIS SCORE (SNAPS) IS SENSITIVE TO CHANGE IN A COHORT OF PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH ETANERCEPT (2020) (0)
Frequencies of TNF alpha, TNF alpha receptor and IL-6 polymorphism in ANCA associated vasculitis (2003) (0)
HLA-DPB1*0101 associations in UK Caucasian adult and juvenile idiopathic inflammatory myopathy patients. (2008) (0)
319. Gender Differences Between Patient Self-Reporting of Raynaud’s Phenomenon and Objective Assessment of Digital Microvascular Perfusion Using Infrared Thermography (2014) (0)
A multicentre study of validity and reliability of measures of cold challenge measured by LSCI and thermography: outcome measures for SSc-related RP (2018) (0)
187 Improvement of psoriatic nail disease in psoriatic arthritis patients treated with adalimumab: results of an observational cohort up to 36 months (2018) (0)
Oral abstracts 1: SpondyloarthropathiesO1. Detecting axial spondyloarthritis amongst primary care back pain referrals (2012) (0)
BILAG-2004 captures SLE disease activity better than SLEDAI-2000 (2005) (0)
Correction to: Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study (2019) (0)
294 Immunophenotypic subgroups of SLE defined by autoantibodies, gene expression and flow cytometric analysis (2019) (0)
I112 New Drugs for Psoriatic Arthritis: The Rheumatologists Perspective—To Include Apremilast, Ustekinumab and Secukinumab (2016) (0)
CHARACTERISTICS OF PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS REQUIRING BIOLOGIC THERAPY IN A UK MULTICENTRE COHORT (2013) (0)
205. The UK Primary Sjögren’s Syndrome Registry (UKPSSR): A Valuable Resource for Future Sjögren’s Syndrom Research (2014) (0)
Genetics [315–318]315. Investigation of Association of the Erap1 Gene with Psoriatic Arthritis (2010) (0)
P265 Burden of psoriatic nail disease and response to biologic therapy in a PsA cohort (2020) (0)
Inflammatory myositis - Foray into the future (2020) (0)
Biopsy pathology in a large cohort of juvenile dermatomyositis is heterogeneous and, for the most part, independent of autoantibody phenotype (2017) (0)
Spondyloarthropathies (Including Psoriatic Arthritis) [40–69] 40. Eagle's Syndrome: An Unusual Association with Sero-Negative Arthropathy (2010) (0)
A qualitative study of patients’ experiences of screening for psoriatic arthritis (2022) (0)
THU0251 IMMUNOPHENOTYPIC CLUSTERS OF SLE PATIENTS REVEAL SUBGROUPS WITH SEVERE DISEASE RESISTANT TO CONVENTIONAL THERAPY (2020) (0)
Patient-centred standards of care for adults with myositis (2017) (0)
Temporal recogntion of epitopes on the sm b polypeptide in two patients (1993) (0)
093 Factors Associated with Sustained Remission in Rheumatoid Arthritis in Patients Treated with Anti-Tumour Necrosis Factor: A Systematic Review (2016) (0)
Molecular mechanisms of disease: osteoarthritisI68. Osteoarthritis (2012) (0)
AB1241 EVALUATION OF A PATIENT COMPLETED DISEASE FLARE QUESTIONNAIRE IN PSORIATIC DISEASE (2020) (0)
POS0705 BILAG-2004 INDEX ACTIVE DISEASE PREDICTS DEVELOPMENT OF DAMAGE (2021) (0)
Newly Described Myositis Autoantibodies: HMGCR, NT5C1A, SAE, PUF60 (2019) (0)
Essentials in rheumatology IP1. Disease Management: Management of Behçet’s Syndrome (2011) (0)
Next generation sequencing of RNA from muscle biopsies shows marked differences between inflammatory myositis, inclusion body myositis, and controls (2013) (0)
47. Specialist Commissioning: Does Treatment by Experts Influence Outcomes for Patients with Rare Diseases? An Exemplar from Myositis (2014) (0)
A p155/140 kDa cancer-associated autoantigen in adult dermatomyositis is a major autoantigen target in juvenile dermatomyositis (2007) (0)
P264 Burden of disease and relative impact of skin and joint disease on quality of life in PsA: analysis from a UK secondary care cohort (2020) (0)
219 Validation of a Distinct Psoriatic Arthritis Risk Variant at IL23R (2016) (0)
The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population (2022) (0)
Clinical Image: skin hyperpigmentation over inflamed joints. (2006) (0)
Health services research, economics and outcomes research 52. Reducing New-to-Follow-up Ratios: No More Easy Solutions (2011) (0)
The Journal of Rheumatology of Psoriatic Arthritis: A Proof-of-concept Study Novel Composite Radiographic Score for Longitudinal Observational Studies (2015) (0)
BILAG BIOLOGICS PROSPECTIVE COHORT: THE USE OF NOVEL BIOLOGICAL THERAPIES IN THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN THE UNITED KINGDOM (2012) (0)
Infections Observed in Rituximab Treated Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register (2015) (0)
POS1034 RESPONSE TO SEQUENTIAL LINES OF BIOLOGICAL THERAPY IN PSORIATIC ARTHRITIS: A SINGLE CENTRE COHORT STUDY (2021) (0)
THU0004 Cross phenotype association mapping of the mhc identifies genetic variants that differentiate psoriatic arthritis from psoriasis (2017) (0)

This paper list is powered by the following services:

Neil John Mchugh's Academic­Influence.com Rankings

Neil John Mchugh's Degrees

Why Is Neil John Mchugh Influential?

Neil John Mchugh's Published Works

Published Works

Neil John Mchugh's AcademicInfluence.com Rankings